BMY Phase 3 readout: a positive outcome, +5.8%

On March 17, 2020, Bristol-Myers Squibb Company reached its Phase 3 readout. The result was a positive outcome, and the stock moved +5.8% in the window around the event. It had already run -17.2% in the 30 days into the catalyst — the kind of pre-event run-up that often precedes binary readouts.